Crinetics Pharmaceuticals (CRNX) Non-Current Assets (2017 - 2026)

Crinetics Pharmaceuticals' Non-Current Assets history runs 10 years deep, the most recent figure standing at $78.9 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 12.29% year-over-year to $78.9 million; the TTM figure through Mar 2026 stood at $303.9 million (up 21.55% YoY), while the FY2025 annual figure was $77.9 million, up 31.6% from the prior year.
• Non-Current Assets for Q1 2026 stood at $78.9 million, up from $77.9 million in the prior quarter.
• The five-year high for Non-Current Assets was $78.9 million in Q1 2026, with the low at $5.0 million in Q1 2022.
• The 5-year median for Non-Current Assets is $60.8 million (2024), against an average of $46.1 million.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets decreased 12.34% in 2022, then surged 903.16% in 2023.
• Crinetics Pharmaceuticals' Non-Current Assets stood at $7.0 million in 2022, then jumped by 775.29% to $61.2 million in 2023, then decreased by 3.26% to $59.2 million in 2024, then surged by 31.6% to $77.9 million in 2025, then increased by 1.28% to $78.9 million in 2026.
• Business Quant data shows CRNX's Non-Current Assets at $78.9 million in Q1 2026, $77.9 million in Q4 2025, and $74.8 million in Q3 2025.